Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05223608 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy

Study acronym: ImmuCCo
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 500 → 651 participantsv8
  2. 2 versions Re-verified since Sep 23, 2025, no change to tracked fieldsv6-v7
  3. Eligibility criteria expanded, about 2 wordsv5
  4. Re-verified, no change to tracked fieldsv4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2022 to Mar 3, 2022
    v3
  6. Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 2 of 5 entries
    • Study description expanded, about 2 words
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.
Trial Details
NCT Number NCT05223608
Lead Sponsor Centre Oscar Lambret
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France
Conditions
(from sponsor)		 Solid Tumor, Adult
Enrollment 651 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov